The U.S. Food and Drug Administration (FDA) authorized an attenuated herpes simplex virus type 1 in 2015, which encodes granulocyte–macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec (T-VEC), as a local therapy for patients suffering from recurrent melanoma, which specifically treats unresectable cutaneous, subcutaneous, and nodal lesions [13,14,15,16,17,18,19,20,21,22,23]. Here, CSF2 is linked to melanoma.